Response to osimertinib plus trametinib in a heavily treated epidermal growth factor receptor (EGFR)-positive NSCLC harboring a rare, acquired rapidly accelerated fibrosarcoma B-type (BRAF) p.D594N mutation: a case report.

Details

Language :

English

ISSN :

09594973

Volume :

33

Issue :

9

Database :

Complementary Index

Journal :

Anti-Cancer Drugs

Publication Type :

Academic Journal

Accession number :

159272108

Full Text :

https://doi.org/10.1097/CAD.0000000000001367